<DOC>
	<DOCNO>NCT01103778</DOCNO>
	<brief_summary>The primary objective study investigate ability Velcade® ( bortezomib ) induce complete partial remission patient severe IgA nephropathy . The secondary objective assess clinical outcome relate safety efficacy , infection , malignancy , preservation renal function , partial responder , relapse rate , study mechanistic assay predict remission .</brief_summary>
	<brief_title>Pilot Study Velcade® IgA Nephropathy</brief_title>
	<detailed_description>This exploratory single center , open-label , single treatment group assignment , safety efficacy study enroll 15 patient severe IgA nephropathy . Subjects receive 1 cycle Velcade® induce clinical remission . Follow-up visit occur monthly year . For pilot study , proportion patient clinical remission partial response analyze . Monetary compensation provide study participant .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Glomerulonephritis , IGA</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>1 . Male female , 18 year age old . 2 . Must IgA nephropathy document kidney biopsy . 3 . Must great 1gm proteinuria day . 4 . Must stable dose Angiotensin Converting Enzyme Inhibitor ( ACEI ) and/or Angiotensin Receptor Blocking agent ( ARB ) least 4 week prior screen . 1 . Low platelet count neutrophil count within certain limit define enrollment . 2 . Underlying peripheral neuropathy . 3 . Having cardiac problem , myocardial infarction , heart failure , uncontrolled angina , severe uncontrolled ventricular arrhythmia , electrocardiographic evidence acute ischemia active conduction system abnormality . 4 . Allergic VELCADE® , boron mannitol . 5 . Female subject pregnant breastfeeding . 6 . Recent use investigational drug within 14 day enrollment . 7 . Having serious medical condition infection ( include HIV , hepatitis B C ) psychiatric illness likely interfere participation study . 8 . Diagnosed treated cancer within 3 year participation study , exception complete resection basal cell carcinoma squamous cell carcinoma skin , situ malignancy , lowrisk prostate cancer curative therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Chronic kidney disease</keyword>
	<keyword>IgA nephropathy</keyword>
	<keyword>Velcade®</keyword>
	<keyword>Proteinuria</keyword>
	<keyword>Bortezomib</keyword>
	<keyword>Proteasome inhibitor</keyword>
</DOC>